GlassScriptPhysician profile
Allyson C Barnes-Finley
NPI 1710549738
$2,646.53
in general payments reported to CMS, 2019-2025
20 companies · $1,081 in 2025
The $1,081 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.06 · 2021: $11.72 · 2022: $50.52 · 2023: $599 · 2024: $890 · 2025: $1,081.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,570.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,570.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $688.12 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $498.14 | 2019-2025 | |
| Exact Sciences Corporation | $292.05 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $268.82 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $241.92 | 2023-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $119.22 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Dynavax Technologies Corporation | $81.97 | 2024-2025 | Heplisav-B |
| Bayer Healthcare Pharmaceuticals INC. | $77.98 | 2023-2025 | |
| Amgen INC. | $76.74 | 2022-2025 | Repatha, Prolia, Evenity |
| Abbvie INC. | $55.30 | 2023-2025 | Qulipta |
| Daiichi Sankyo INC. | $37.71 | 2024 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.03 | 2025 | Jardiance |
| Axsome Therapeutics, INC. | $29.77 | 2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.44 | 2024 | Xifaxan |
| Phadia US INC. | $22.22 | 2024 | Immunocap |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $20.28 | 2025 | |
| Astellas Pharma US INC | $20.00 | 2025 | Veozah |
| Lucid Diagnostics INC. | $19.39 | 2023 | |
| Shield Therapeutics INC | $18.80 | 2024 | |
| Nevro Corp. | $16.63 | 2024 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allyson Barnes-Finley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.